Artículos por temáticas

The amyloid cascade-inflammatory hypothesis of Alzheimer disease: implications for therapy

McGeer PL, McGeer EG.

Acta Neuropathol. 2013 Oct;126(4):479-97. doi: 10.1007/s00401-013-1177-7. Epub 2013 Sep 20.

Alzheimer disease: from biomarkers to diagnosis

Dubois B, Epelbaum S, Santos A, Di Stefano F, Julian A, Michon A, Sarazin M, Hampel H.

Rev Neurol (Paris). 2013 Oct;169(10):744-51. doi: 10.1016/j.neurol.2013.07.016. Epub 2013 Sep 13.

Towards an earlier diagnosis of Alzheimer's disease presenting with visuospatial disorders (posterior cortical atrophy)

Vighetto A.

Rev Neurol (Paris). 2013 Oct;169(10):687-94. doi: 10.1016/j.neurol.2013.08.001. Epub 2013 Sep 12.

[Genetic aspects of Alzheimer's disease (Review)]

El Kadmiri N, Hamzi K, El Moutawakil B, Slassi I, Nadifi S.

Pathol Biol (Paris). 2013 Dec;61(6):228-38. doi: 10.1016/j.patbio.2013.04.001. Epub 2013 Sep 10.

Understanding cognitive deficits in Alzheimer's disease based on neuroimaging findings

Braskie MN, Thompson PM.

Trends Cogn Sci. 2013 Oct;17(10):510-6. doi: 10.1016/j.tics.2013.08.007. Epub 2013 Sep 9.

Biomarkers of Alzheimer's disease: the present and the future

Lehmann S, Delaby C, Touchon J, Hirtz C, Gabelle A.

Rev Neurol (Paris). 2013 Oct;169(10):719-23. doi: 10.1016/j.neurol.2013.07.012. Epub 2013 Sep 7.

Clinical indications for analysis of Alzheimer's disease CSF biomarkers

Engelborghs S.

Rev Neurol (Paris). 2013 Oct;169(10):709-14. doi: 10.1016/j.neurol.2013.07.024. Epub 2013 Sep 6.

Disease-specific adaptive immune biomarkers in Alzheimer's disease and related pathologies

Dorothée G, Sarazin M, Aucouturier P.

Rev Neurol (Paris). 2013 Oct;169(10):715-8. doi: 10.1016/j.neurol.2013.07.023. Epub 2013 Sep 6.

Neuroimaging biomarkers for Alzheimer's disease in asymptomatic APOE4 carriers

Chételat G, Fouquet M.

Rev Neurol (Paris). 2013 Oct;169(10):729-36. doi: 10.1016/j.neurol.2013.07.025. Epub 2013 Sep 6.

From biomarkers to cytokine-like hormones: uncovering new directives for cognitive loss and Alzheimer's disease

Maiese K.

Curr Neurovasc Res. 2013 Nov;10(4):275-7. doi: 10.2174/15672026113109990033.

Amyloid imaging: the court of public opinion

Lerner AJ.

Neurology. 2013 Sep 24;81(13):1108-9. doi: 10.1212/WNL.0b013e3182a55fe3. Epub 2013 Aug 21.

Clinical assessment of amyloid imaging in Alzheimer's disease: a systematic review of the literature

Wahlster P, Niederländer C, Kriza C, Schaller S, Kolominsky-Rabas PL.

Dement Geriatr Cogn Disord. 2013;36(5-6):263-78. doi: 10.1159/000351679. Epub 2013 Aug 16.

Effects of memantine on clinical ratings, fluorodeoxyglucose positron emission tomography measurements, and cerebrospinal fluid assays in patients with moderate to severe Alzheimer dementia: a 24-week, randomized, clinical trial

Wang T, Huang Q, Reiman EM, Chen K, Li X, Li G, Lin Z, Li C, Xiao S.

J Clin Psychopharmacol. 2013 Oct;33(5):636-42. doi: 10.1097/JCP.0b013e31829a876a.

Inflammatory components in human Alzheimer's disease and after active amyloid-β42 immunization

Zotova E, Bharambe V, Cheaveau M, Morgan W, Holmes C, Harris S, Neal JW, Love S, Nicoll JA, Boche D.

Brain. 2013 Sep;136(Pt 9):2677-96. doi: 10.1093/brain/awt210. Epub 2013 Aug 13.

Platelet-derived secreted amyloid-precursor protein-β as a marker for diagnosing Alzheimer's disease

Marksteiner J, Humpel C.

Curr Neurovasc Res. 2013 Nov;10(4):297-303. doi: 10.2174/15672026113109990022.